News

Kiadis Pharma Receives Regulatory Approval from Health Canada for a Phase II Clinical Study with its Blood Cancer Treatment ATIR™ 26-02-2013
Amsterdam, The Netherlands, February 26, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today it has received the No Objection Letter from Health Canada for its new clinical study with ATIR™. This study will be a Phase II... read more 

Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™ 21-01-2013
Amsterdam, The Netherlands, January 21, 2013 – Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that it has received a Notice of Allowance for its U.S. Patent Application No. 10/969,011 regarding the Company’s lead product... read more 

Pipeline

Kiadis Pharma product portfolio

Kiadis Pharma has a number of novel products in clinical development..Its lead product ATIR™ addresses the shortage in availability of matched donors by enabling transplantations from partially matched (haploidentical) donors who are readily available within the patient’s family. ATIR™ is currently in Phase II of clinical development. Furthermore, with Rhitol™ and Reviroc™, Kiadis Pharma has two other cell-based product candidates in hemato-oncological indications in development (chronic Graft versus Host Disease and autologous transplantation respectively).

 

The current status of our products in clinical development:

 

 

  • ATIR™: Phase I/II study for hematopoietic stem cell transplantation (HSCT) closed for enrollment; 5-year follow-up nearly complete
  • Rhitol™: Phase I/II study completed
  • Reviroc™: Phase I study completed